林奇综合征上消化道内镜筛查结局的荟萃分析
该荟萃分析检索至2021年12月,纳入9项研究、2356例林奇综合征患者共约7838次食管胃十二指肠镜检查,汇总计算上消化道肿瘤、高危病变及临床可干预发现的检出率,并评估不同错配修复基因间胃癌或十二指肠癌检出有无差异。
要点
- 林奇综合征患者上消化道肿瘤汇总检出率为0.9%(95%CI 0.3-2.1;I²=89%)。
- 高危病变汇总检出率为4.2%(95%CI 1.6-10.9;I²=98%),临床可干预发现为6.2%(95%CI 2.2-16.5;I²=99%)。
- 林奇综合征相关基因与胃癌或十二指肠癌检出之间无差异。
核心结论
- 在林奇综合征中,有证据表明内镜筛查可检出上消化道肿瘤、癌前病变及其他临床可干预发现,支持将其作为林奇综合征癌症风险管理的一部分。
研究设计与样本
- 系统检索至2021年12月的数据库,纳入9项评估林奇综合征患者食管胃十二指肠镜筛查的研究,共2356例患者、约7838次食管胃十二指肠镜检查。
- 采用随机效应模型计算Mantel-Haenszel汇总比值比及95%置信区间,并计算检出事件的汇总率,使用I²统计量评估统计异质性。
主要发现
- 共识别47例林奇综合征相关上消化道肿瘤(18例胃癌、29例十二指肠癌)、237例高危病变和335例临床可干预发现。
- 筛查中任何上消化道肿瘤的汇总检出率为0.9%(95%CI 0.3-2.1;I²=89%)。
- 高危病变的汇总检出率为4.2%(95%CI 1.6-10.9;I²=98%)。
- 临床可干预发现的汇总检出率为6.2%(95%CI 2.2-16.5;I²=99%)。
- 林奇综合征相关基因与胃癌或十二指肠癌检出之间无差异。
关键数值与推荐
- 任何上消化道肿瘤检出率0.9%(95%CI 0.3-2.1;I²=89%)。
- 高危病变检出率4.2%(95%CI 1.6-10.9;I²=98%)。
- 临床可干预发现检出率6.2%(95%CI 2.2-16.5;I²=99%)。
临床怎么用
- 原文结论认为有证据支持将内镜筛查作为林奇综合征癌症风险管理的一部分,原文未据此给出具体推荐条款。
局限性
- 肿瘤检出率、高危病变检出率和临床可干预发现检出率的异质性分别为I²=89%、I²=98%和I²=99%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Lynch syndrome (LS) predisposes affected individuals to a high lifetime risk of malignancies, including colorectal, endometrial, gastric, and duodenal cancers. The role of upper GI (UGI) cancer screening in LS has been uncertain, but recent studies have evaluated its utility. METHODS: Databases were queried through December 2021 to identify studies that examined upper endoscopy screening in LS using EGD. Mantel-Haenszel pooled odds ratios and 95% confidence intervals (CIs) for outcomes were constructed using a random-effects model to identify pooled odds of endoscopic findings in persons with LS. Event rates for detection of gastric and duodenal cancers, high-risk lesions, and clinically actionable findings were calculated. Statistical heterogeneity was assessed using the I2 statistic. RESULTS: Nine studies were identified with 2356 LS patients undergoing approximately 7838 EGDs. In total, 47 LS-associated UGI cancers (18 gastric and 29 duodenal cancers), 237 high-risk lesions, and 335 clinically actionable findings were identified. The pooled event rate for detection of any UGI cancer, high-risk lesions, and clinically actionable findings during screening were .9% (95% CI, .3-2.1; I2 = 89%), 4.2% (95% CI, 1.6-10.9; I2 = 98%), and 6.2% (95% CI, 2.2-16.5; I2 = 99%), respectively. There was no difference between LS-associated gene and gastric or duodenal cancer detection. CONCLUSIONS: In LS, there is evidence that endoscopic screening detects UGI cancers, precancerous lesions, and other clinically actionable findings that favor its use as a part of cancer risk management in LS.
引用
- Vedantam S, Katona BW, Sussman DA, et al. Outcomes of upper endoscopy screening in Lynch syndrome: a meta-analysis. Gastrointest Endosc. 2022. PMID: 36084717. doi:10.1016/j.gie.2022.08.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。